AEB071 - A promising immunosuppressive agent

Clinical Transplantation

Volumn 23, Issue SUPPL.21, 2009, Pages 15-18

  Sommerer, Claudia ^a   Zeier, Martin ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

AEB071; Immunosuppression; Protein kinase C; Renal transplantation

Indexed keywords

AEB 701; CYCLOPHILIN; CYCLOSPORIN A; CYTOCHROME P450 3A; EVEROLIMUS; FINGOLIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; SOTRASTAURIN; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; AREA UNDER THE CURVE; CELL PROLIFERATION; CLINICAL TRIAL; DIARRHEA; DOWN REGULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; GENE ACTIVATION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; ORGAN TRANSPLANTATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PSORIASIS; REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VOMITING;

CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PYRROLES; QUINAZOLINES;

EID: 70649093707     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01104.x     Document Type: Review

References (26)

1. Wolfe RA, Ashby VB, Milford EL. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999, 341:1725.
2. Kahan BD. Ciclosporin. N Engl J Med 1989, 321:1725.
3. Hariharan S, Johnson CP, Bresnahan BA. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000, 342:605.
4. Nankivell BJ, Borrows RJ, Fung CL. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004, 78:557.
5. Sommerer C, Hergesell O, Nahm AM. Cyclosporin A toxicity of the renal allograft - a late complication and potentially reversible. Nephron 2002, 92:339.
6. Dantal J, Hourmant M, Cantarovich D. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998, 351:623.
7. Meier M, Nitschke M, Weidtmann B. Slowing the progression of chronic allograft nephropathy by conversion from ciclosporin to tacrolimus: a randomized controlled trial. Transplantation 2006, 81:1035.
8. Grinyo JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transpl 2006, 6:1991.
9. Evenou JP, Brinkmann V, Towbin H. Enzymatic and cellular characterization of NVP-AEB071 (AEB), a novel and selective protein kinase C (PKC) inhibitor that blocks early T celll activation, and its use to define the role of PKC in T cells. [Abstract]. Am J Transplant 2006, 6:S1026.
10. Evenou JP, Wagner J, Zenke G. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation. J Pharmacol Exp Ther 2009, 330:792.
11. Spitaler M, Cantrell DA. Protein kinase C and beyond. Nat Immunol 2004, 5.
12. Mackay HJ, Twelves CM. Targeting the protein kinase C family: are we there yet?. Nat Rev Cancer 2007, 7:554.
13. Leitges M. Functional PKC in vivo analysis using deficient mouse models. Biochem Soc Trans 2007, 35:1080.
14. Burkhart C, Maassen J, Vogt G, Gasser R, Beerli C, Weckbecker G. Blood PK and PD measurements of the novel protein kinase C inhibitor NVP-AEB071 (AEB) correlate with heart allograft survival times in rat. [Abstract]. Am J Transpl 2007, 7:S427.
15. Bigaud M, Wieczorek G, Riesen S. NVP-AEB071, a novel oral inhibitor of early T-cell activation, prolongs the survival of non-human primate kidney allografts when used as monotherapy or at non-effective doses combined whith a non-effective dose of cyclosporin (CsA). [Abstract]. Am J Transpl 2006, 6:S250.
16. Bigaud M, Wieczorek G, Preussing E. NVP-AEB071 (AEB), the novel oral inhibitor of protein kinase C (PKC) and early T-cell activation, prolongs non-human primates kidney allograft survival when combined with everolimus, ERL080 or FTY720 without calcineurin inhibitor. [Abstract]. Am J Transplant 2006, 6:S251.
17. Bruns C, Pally C, Beerli C. NVP-AEB071 (AEB), a novel oral inhibitor of early T-cell activation, prolongs rat cardiac allograft survival when used alone and in combination with cyclosporine, everolimus or FTY720. [Abstract]. Am J Transpl 2006, 6:S316.
18. Slade A, Marbach P, Burkhart C, Seiberling M, Schmouder R. NVP-AEB071: safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses from 10 to 1100 mg. [Abstract]. Am J Transpl 2007, 7:S183.
19. Skvara H, Dawid M, Kleyn E. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest 2008, 118:3151.
20. Weckbecker G, Jean C, Pally C. Pharmacokinetics of the novel oral protein kinase C inhibitor NVP-AEB071 in rats and non-human primates (NHP): study of immunosuppressive efficacy and distribution to lymphatic organs. [Abstract]. Am J Transpl 2006, 6:S768.
21. Jin Y, Pfister C, Marbach P, Fischer V. Predictions of clinical drug interactions of AEB071 using Simdyp simulations: potential applications in drug development. [Abstract]. Am J Transpl 2007, 7:S347.
22. Burkhart C, Welzenbach K, Raulf F. First escalating single dose human volunteer study of the novel immunosuppressant NVP-AEB071 (AEB): relationships among dose levels, PK and PD of immune functions. [Abstract]. Am J Transplant 2006, 6:S698.
23. Matz M, Weber UA, Kramer S, Glander P, Neumayer HH, Budde K. Effects of the new immunosuppressive agent AEB071 on T-cell activation in vitro. [Abstract]. Am J Transpl 2007, 7:S1736.
24. Vinenti F, Kirk AD. What's next in the pipeline. Am J Transplant 2008, 8:1972.
25. Budde K, Sommerer C, Becker T. AEB071, a novel protein kinase C-inhibitor: first clinical results of an AEB071 plus tacrolimus regimen in renal transplant recipients [Abstract]. Am J Transplant 2009, 9:S304.
26. Friman S, Arns W, Banas B. AEB071, a novel protein kinas C-inhibitor: evaluation of an AEB071 plus mycophenolate regimen in renal transplant recipients [Abstract]. Am J Transplant 2009, 9:S323.